Linvoseltamab in combination with carfilzomib or bortezomib shows promising initial results in earlier lines of treatment for relapsed/refractory multiple myeloma

First results to be presented in two asco oral presentations data in both combinations demonstrate high response rates tarrytown, n.y., may 22, 2025 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced initial results from two cohorts of the phase 1b linker-mm2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors (pi) – carfilzomib or bortezomib – in patients with relapsed/refractory (r/r) multiple myeloma (mm).
REGN Ratings Summary
REGN Quant Ranking